Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings

Simple item page
dc.contributor.authorWayengera, Misaki
dc.contributor.authorKajumbula, Henry
dc.contributor.authorByarugaba, Wilson
dc.date.accessioned2021-12-12T18:37:41Z
dc.date.available2021-12-12T18:37:41Z
dc.date.issued2008
dc.description.abstractThe highest burden of the human immunodeficiency virus (HIV) epidemic is concentrated in the sub-Saharan region. Over 70% of all global HIV infections have been found to occur here [1]. Despite the earlier policy and patent controversies surrounding the use of highly active antiretroviral therapy (HAART) within this setting, HAART has widely gained application here [2]. This access to HAART can be mainly attributed to several advocacy and funding avenues [2-4]. Specifically, the World Bank and its global partners, in particular, with commitment by the G8, have ensured that several countries within this setting can meet the WHO 3’by 5” target of treating 3 million by 2005 [3,4].en_US
dc.identifier.citationWayengera, M., Kajumbula, H., & Byarugaba, W. (2008). Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings. The open AIDS journal , 2 , 78.en_US
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/pmc2627514/
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/377
dc.language.isoenen_US
dc.publisherThe open AIDS journalen_US
dc.subjectAcquired immunodeficiency syndrome(AIDS)en_US
dc.subjectHighly active antiretroviral therapy (HAART)en_US
dc.subjectHuman immunodeficiency virus (HIV)en_US
dc.subjectDrug resistanceen_US
dc.titleHarnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settingsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings.pdf
Size:
66.28 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences